Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Tetra Bio Pharma Inc TBPMQ

Tetra Bio-Pharma Inc. is a Canada-based cannabinoid-derived drug discovery and development company. The Company has developed a pipeline of cannabinoid-based drug products for a range of medical conditions, including pain, inflammation, and oncology. The Company has a pipeline of formulations and drug delivery systems with a portfolio of assets from the early research and development phase to... see more

GREY:TBPMQ - Post Discussion

Tetra Bio Pharma Inc > Tetra Bio-Pharma Provides Update on Research Collaboration
View:
Post by Betteryear2 on Mar 08, 2022 7:20am

Tetra Bio-Pharma Provides Update on Research Collaboration

  • Health Canada approved the amendment of the phase I study to assess the effect of low and moderate doses of inhaled CBD in healthy cannabinoid users.
  • The collaboration with the CRCHUM will allow Tetra to obtain phase I clinical data on inhaled CBD.

OTTAWA, ONMarch 8, 2022 /PRNewswire/ - Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-derived drug discovery and development announced today that Health Canada approved the amendment of a phase I study conducted in collaboration with Dr. Jutras-Aswad and the University of Montreal Hospital Research Centre (Centre de recherche du Centre hospitalier de l'Universit de Montral, ("CRCHUM"). The study will assess the safety profile of low and moderate doses of inhaled CBD and determine the cognitive, behavioral, and biological effects of CBD in adults who occasionally use cannabis. The clinical trial has been authorized by Health Canada, who also recently approved an amendment to the research protocol to increase the dosage of the study drug up to 100 mg of CBD to be assessed in the study.

Comment by Golddetector on Mar 08, 2022 9:17am
Not sure how this works with the current company projects of QIXLEEF. It looks something separate totally. Anyway the study sponsored by others. It is going to clinical trials phase i. 
Comment by Savage97 on Mar 08, 2022 10:30am
Partnerships Growing!!!!!!!!!!!!!!!!$$$!!!!!!!!!!!!!!!TBP!!!!!!!!!!!!!!!!$$$!!!!!!!!!!!!!!!!!!
Comment by DONOOW on Mar 08, 2022 10:51am
Investors are waiting for approvals ,not a partnership per month ! an the SP is sinking every week lower !
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities